June 9, 2026
Deadline to register:
June 8, 2026, 5 PM ET
8:00 AM Pacific Time
*Note: You must register to be eligible to participate in the meeting.
Design Therapeutics is a clinical-stage biopharmaceutical company advancing novel, small molecule therapeutic candidates designed to bring functional cures to serious genetic diseases with long-standing unmet need. Through our GeneTAC® (Gene Targeted Chimera) platform, we are leveraging our deep understanding of gene regulation and the tried-and-true power of small molecules to develop therapeutic candidates that target the underlying cause of genetic disorders.
We are advancing a pipeline of novel candidates with an initial focus on monogenic repeat expansion disorders with urgent medical need, including Friedreich ataxia, Fuchs endothelial corneal dystrophy, myotonic dystrophy and Huntington’s disease.
